91,337 Shares in Halozyme Therapeutics, Inc. (NASDAQ:HALO) Bought by Chase Investment Counsel Corp

Chase Investment Counsel Corp bought a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 91,337 shares of the biopharmaceutical company’s stock, valued at approximately $4,782,000. Halozyme Therapeutics comprises 1.6% of Chase Investment Counsel Corp’s portfolio, making the stock its 19th biggest position.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Rise Advisors LLC bought a new position in Halozyme Therapeutics during the first quarter valued at $25,000. Whittier Trust Co. purchased a new stake in shares of Halozyme Therapeutics in the first quarter valued at $27,000. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 96.6% in the second quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 254 shares during the period. International Assets Investment Management LLC purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at $33,000. Finally, Skandinaviska Enskilda Banken AB publ purchased a new stake in shares of Halozyme Therapeutics in the second quarter valued at $49,000. Institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 0.0 %

NASDAQ:HALO opened at $56.97 on Monday. Halozyme Therapeutics, Inc. has a fifty-two week low of $32.83 and a fifty-two week high of $65.53. The stock has a market capitalization of $7.25 billion, a P/E ratio of 23.54, a P/E/G ratio of 0.56 and a beta of 1.28. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41. The company’s 50-day simple moving average is $58.67 and its 200-day simple moving average is $49.79.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. During the same period last year, the business earned $0.68 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. On average, equities analysts anticipate that Halozyme Therapeutics, Inc. will post 3.71 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently commented on the stock. TD Cowen raised their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. JPMorgan Chase & Co. downgraded shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their target price for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. Wells Fargo & Company raised their target price on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research report on Friday, June 7th. Morgan Stanley raised their target price on shares of Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Finally, HC Wainwright reissued a “buy” rating and set a $65.00 target price on shares of Halozyme Therapeutics in a research report on Friday, September 13th. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $60.00.

Insider Buying and Selling

In related news, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $56.34, for a total value of $563,400.00. Following the completion of the sale, the chief executive officer now directly owns 676,744 shares in the company, valued at approximately $38,127,756.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 9,881 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total transaction of $570,133.70. Following the completion of the sale, the director now directly owns 69,874 shares in the company, valued at approximately $4,031,729.80. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $56.34, for a total transaction of $563,400.00. Following the sale, the chief executive officer now owns 676,744 shares of the company’s stock, valued at $38,127,756.96. The disclosure for this sale can be found here. Insiders sold 84,881 shares of company stock worth $4,932,284 in the last three months. Corporate insiders own 2.40% of the company’s stock.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.